4basebio PLC (LON:4BB – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of GBX 522.10 and traded as low as GBX 500. 4basebio shares last traded at GBX 500, with a volume of 45 shares traded.
4basebio Price Performance
The firm’s fifty day moving average is GBX 524.74 and its 200-day moving average is GBX 522.10. The stock has a market capitalization of £82.07 million, a price-to-earnings ratio of -4.57 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.
4basebio (LON:4BB – Get Free Report) last released its earnings results on Monday, September 28th. The company reported GBX (0.57) EPS for the quarter. On average, sell-side analysts predict that 4basebio PLC will post -3.43 earnings per share for the current year.
About 4basebio
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Further Reading
- Five stocks we like better than 4basebio
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
